1. Gemcitabine Combined With Uracil-Tegafur in Patients With Advanced Pancreatic Cancer
- Author
-
Metin Ozkan, Banu Ozturk, Aytug Uner, Ozlem Er, Ulkö Yalcintas Aslan, Mustafa Benekli, Ramazan Yildiz, Söleyman Buyukberber, Alper Sevinc, Gokhan Celenkoglu, Saadet Tokluoglu, Ugur Coskun, Celalettin Camci, and Necati Alkis
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pancreatic disease ,medicine.drug_class ,medicine.medical_treatment ,Deoxycytidine ,Antimetabolite ,Tegafur ,Gastroenterology ,Pancreatic cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Uracil ,Aged ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,business.industry ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Gemcitabine ,Surgery ,Pancreatic Neoplasms ,Survival Rate ,Regimen ,Treatment Outcome ,Female ,business ,medicine.drug - Abstract
The aim of the study was to evaluate the efficacy and tolerability of gemcitabine and uracil-tegafur (LIFT) combination in patients with advanced pancreatic carcinoma, retrospectively. Thirty-one patients, including 27 with metastatic disease, were treated with gemcitabine at a dose of 1000 Mg/m(2) in 30 minutes on days 1 and 8, and oral UFT 300 mg/m(2) on days 1-14, as the first-line regimen in advanced stage. The cycle was repeated every 21 days. A total of 116 cycles of chemotherapy were administered, with a median of 3 cycles per patient (range 1-13). The objective response rate was observed in 6 (19.3%) patients with 1 (3.2%) complete response, and 5 (16.1%) partial responses. The median response duration was 4 (range, 3-14) months. Eight (25.8%) patients had a standard deviation of more than 3 months. Median overall survival was 8 months (95% Cl, 6-10 months) and median time to progression was 4.2 months (95% Cl, 1-6 months). This combination was generally well tolerated. There were no life-threatening side effects. Most common toxicities were of hematologic and gastrointestinal nature. In conclusion, this regimen was well tolerated and seemed to have a moderate activity in the palliative treatment of advanced pancreatic carcinoma.
- Published
- 2009